NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Shares of Henry Schein split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has approved a share buyback plan on Thursday, December 13th 2018, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's management believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings results on Monday, August, 6th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.31 billion. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.88 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Henry Schein.

Henry Schein will be holding an earnings conference call on Wednesday, February 20th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

17 Wall Street analysts have issued 12-month price objectives for Henry Schein's stock. Their forecasts range from $66.00 to $102.00. On average, they expect Henry Schein's stock price to reach $82.7327 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Henry Schein.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 4 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Media coverage about HSIC stock has been trending neutral on Saturday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.

Some companies that are related to Henry Schein include Edwards Lifesciences (EW), Takeda Pharmaceutical (TKPYY), Actelion (ALIOF), FRESENIUS SE &/S (FSNUY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), ESSILOR INTL S/S (ESLOY), Centene (CNC), McKesson (MCK), Zimmer Biomet (ZBH), Fresenius Medical Care AG & Co. (FMS), Eisai (ESALY), TERUMO CORP/ADR (TRUMY), LONZA GRP AG/ADR (LZAGY) and Canopy Growth (WEED).

Henry Schein's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Longview Partners Guernsey LTD (8.67%), BlackRock Inc. (7.29%), Atlanta Capital Management Co. L L C (4.10%), Alecta Pensionsforsakring Omsesidigt (2.87%), Mackenzie Financial Corp (2.65%) and Geode Capital Management LLC (1.38%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Park West Asset Management LLC, Alecta Pensionsforsakring Omsesidigt, Mackenzie Financial Corp, Longview Partners Guernsey LTD, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Swedbank and SG Americas Securities LLC. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, BlackRock Inc., Retirement Systems of Alabama, State of Tennessee Treasury Department, California Public Employees Retirement System, D. E. Shaw & Co. Inc., First Trust Advisors LP and Prudential PLC. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $62.39.

Henry Schein has a market capitalization of $9.51 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]